Immutep: A leader in a league alongside global Pharma giants
Immutep’s (IMM.ASX) lead product candidate LAG-3Ig is currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for various cancer indications.
Read More